TY - JOUR
T1 - The PARTHENON Clinical Development Program
T2 - the Role of Ticagrelor in Patients with Atherothrombotic Disease
AU - Dobesh, Paul P.
AU - Patel, Manesh
N1 - Funding Information:
Acknowledgements Editorial support was provided by Lucy Carty and Kerren Davenport, Prime, Knutsford, Cheshire, UK. Prime has received funding support from AstraZeneca.
Publisher Copyright:
© 2017, The Author(s).
PY - 2017/8/1
Y1 - 2017/8/1
N2 - Although the rate of cardiovascular disease (CVD)-related mortality has declined over the last decade, it is still the leading cause of mortality in the USA, accounting for over 1.4 million deaths annually. In addition, total direct (primarily hospital admissions) and indirect costs of CVD in the US is over 316 billion annually and is expected to grow to over 918 billion by 2030. Much of the etiology of CVD is due to atherosclerosis and its thrombotic complications, and central to this is the role of platelets. Atherosclerosis is a systemic disease, with meaningful morbidity and mortality when present in the coronary, cerebral, or major peripheral arteries. The recommended antiplatelet therapy differs based on the vascular bed impacted, with the optimal antiplatelet therapy yet to be defined. The PARTHENON program is a series of completed and ongoing phase III clinical trials investigating the efficacy and safety of ticagrelor in atherosclerotic CVD in comparison with established antiplatelet therapy or placebo. The overall aim of the program is to determine if more potent antiplatelet therapy, with different pharmacology, may reduce cardiovascular events in patients with atherosclerotic disease.
AB - Although the rate of cardiovascular disease (CVD)-related mortality has declined over the last decade, it is still the leading cause of mortality in the USA, accounting for over 1.4 million deaths annually. In addition, total direct (primarily hospital admissions) and indirect costs of CVD in the US is over 316 billion annually and is expected to grow to over 918 billion by 2030. Much of the etiology of CVD is due to atherosclerosis and its thrombotic complications, and central to this is the role of platelets. Atherosclerosis is a systemic disease, with meaningful morbidity and mortality when present in the coronary, cerebral, or major peripheral arteries. The recommended antiplatelet therapy differs based on the vascular bed impacted, with the optimal antiplatelet therapy yet to be defined. The PARTHENON program is a series of completed and ongoing phase III clinical trials investigating the efficacy and safety of ticagrelor in atherosclerotic CVD in comparison with established antiplatelet therapy or placebo. The overall aim of the program is to determine if more potent antiplatelet therapy, with different pharmacology, may reduce cardiovascular events in patients with atherosclerotic disease.
KW - Acute coronary syndrome
KW - Cardiovascular disease
KW - Parthenon
KW - Ticagrelor
UR - http://www.scopus.com/inward/record.url?scp=85028772052&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85028772052&partnerID=8YFLogxK
U2 - 10.1007/s10557-017-6749-7
DO - 10.1007/s10557-017-6749-7
M3 - Review article
C2 - 28866767
AN - SCOPUS:85028772052
SN - 0920-3206
VL - 31
SP - 433
EP - 444
JO - Cardiovascular Drugs and Therapy
JF - Cardiovascular Drugs and Therapy
IS - 4
ER -